PBA-modified PAD4 inhibitors demonstrated a significant decrease in the formation of NETs in the tumor tissues and were able to inhibit the growth and metastasis of breast cancer in the in vivo 4T1-homozygous mouse model in a concentration-dependent manner. This evidence concerns the gene PADI4 and breast carcinoma.